The therapeutic potential of FGF21 in stroke has been indicated by studies in animal models [25]; however, the main limitation for a future translational application is the side effects of other related factors, such as FGF2 and FGF23, in clinical trials with stroke patients [25]. The gene discussed is FGF2; the disease is Stroke.